HANDA PHARMACEUTICALS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 137 TWD | -2.49% |
|
+13.22% | -25.34% |
Valuation
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Capitalization 1 | 25,891 | 19,329 |
| Enterprise Value (EV) 1 | 25,224 | 16,110 |
| P/E ratio | 34 x | 8.57 x |
| Yield | - | - |
| Capitalization / Revenue | 23.4 x | 7.58 x |
| EV / Revenue | 22.8 x | 6.32 x |
| EV / EBITDA | 35.7 x | 7.06 x |
| EV / FCF | - | 8.43 x |
| FCF Yield | - | 11.9% |
| Price to Book | 8.94 x | 4.49 x |
| Nbr of stocks (in thousands) | 141,094 | 141,088 |
| Reference price 2 | 183.5 | 137.0 |
| Announcement Date | 4/2/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | 1,106 | 2,550 |
| EBITDA 1 | - | 705.9 | 2,282 |
| EBIT 1 | - | 693.4 | 2,241 |
| Operating Margin | - | 62.68% | 87.88% |
| Earnings before Tax (EBT) 1 | - | 792.5 | 2,243 |
| Net income 1 | -40.01 | 726.9 | 2,080 |
| Net margin | - | 65.7% | 81.57% |
| EPS 2 | - | 5.400 | 15.98 |
| Free Cash Flow 1 | - | - | 1,910 |
| FCF margin | - | - | 74.9% |
| FCF Conversion (EBITDA) | - | - | 83.7% |
| FCF Conversion (Net income) | - | - | 91.83% |
| Dividend per Share | - | - | - |
| Announcement Date | 4/21/23 | 4/2/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales 1 | 566.3 | 540.1 |
| EBITDA 1 | 407.3 | 298.5 |
| EBIT 1 | 400.4 | 293.1 |
| Operating Margin | 70.7% | 54.27% |
| Earnings before Tax (EBT) 1 | 481.7 | 310.8 |
| Net income 1 | 494 | 232.9 |
| Net margin | 87.24% | 43.12% |
| EPS 2 | 3.780 | 1.620 |
| Dividend per Share | - | - |
| Announcement Date | 8/14/23 | 4/2/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | - | 667 | 3,219 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow 1 | - | - | 1,910 |
| ROE (net income / shareholders' equity) | - | 41.8% | 70.9% |
| ROA (Net income/ Total Assets) | - | 38% | 69.3% |
| Assets 1 | - | 1,914 | 3,001 |
| Book Value Per Share 2 | - | 20.50 | 30.50 |
| Cash Flow per Share 2 | - | - | 14.70 |
| Capex 1 | - | - | 2 |
| Capex / Sales | - | - | 0.08% |
| Announcement Date | 4/21/23 | 4/2/24 | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
137
TWD
Average target price
200
TWD
Spread / Average Target
+45.99%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.34% | 611M | |
| +22.69% | 43.81B | |
| +25.56% | 23.01B | |
| +18.00% | 15.27B | |
| +8.91% | 13.68B | |
| +42.72% | 11.96B | |
| -7.49% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.59B |
- Stock Market
- Equities
- 6620 Stock
- Financials Handa Pharmaceuticals, Inc.
